All Insights

Outcomes Articles

The Quarter Is Under Pressure. Which Five-Year Bets Do You Protect?

November 10, 2026


About This Report

Consider a hypothetical budget review: a quarterly shortfall puts a development program on the cut list. Reducing its funding could help close the gap. But what does that reduction save now, and what does it delay or remove from the company's future? Finance, strategy and R&D leaders need both answers.

At The MedTech Conference, the panel discussed investments in products that might not launch for two to five years alongside the obligation to execute well in the current quarter. That combination makes the budget choice harder. A program can matter to the company's future and still need scrutiny today. Its distance from revenue doesn't settle whether it deserves continued funding. John Babitt, EY partner and global MedTech leader, moderated "Pulse on Medtech: The Best Opportunities in Medtech for 2026-2027" at The MedTech Conference. The panel included Mick Farrell (ResMed chairman and CEO), Michael Mahoney (Boston Scientific chairman and CEO), Robbie Marcus (J.P. Morgan MedTech analyst), and Ashley McEvoy (Insulet president and CEO).

Show What the Proposed Cut Takes Away

Start by naming what the company needs to be able to do five years from now. Then connect the proposed cut to that capability. A spending category alone won't show the consequence. Leaders need to understand which part of the future portfolio the commitment supports and what would change if its funding were reduced.

The panel described a portfolio that combines internal R&D, acquisitions and venture investments to support longer-term growth. Some products under development might remain years from launch. The discussion also acknowledged the uncertainty involved, including venture companies that don't work out. The rationale was to keep building a differentiated portfolio through difficult periods, with the recognition that individual investments can fail.

That requires more precision than calling something strategic. If the proposed reduction affects internal development, which capability would arrive later, become narrower or no longer be pursued? If it affects an external investment, what opportunity would the company relinquish? These are questions for the review, not consequences to assume before examining the work.

A five-year ambition alone doesn't establish that today's spending deserves protection. Leaders need to explain the connection between the commitment and the capability they want. Where that connection is weak, narrowing or stopping the investment may be justified. Where it is strong, the future consequence belongs alongside the immediate savings.

Protect Long-Term Work With Clear Near-Term Expectations

Keeping a program funded means defining progress before its eventual launch. A product two to five years from revenue still needs a useful expectation for the current quarter. The question is what the team should learn, resolve or demonstrate before the next funding decision.

A team years from launch may need to establish a technical result or test an assumption before it can justify more funding. Immediate revenue may be the wrong test. Repeating the promise of future value is too weak a test.

Write the next expectation in terms that would change the decision. A result might support continued investment, expose a need to narrow the work or undermine the original rationale. Protecting the program should preserve its opportunity to earn the next commitment.

Decide Where Verified Productivity Gains Will Go

Operational improvements could give leaders another way to support the work they've chosen to retain. The panel raised the possibility that AI could improve productivity and release resources for clinical science or R&D. It also emphasized how much work remained. That is a potential funding source, with gains still to be demonstrated.

Before those resources enter a budget decision, leaders need to establish what actually improved and what became available as a result. A task completed faster may release staff capacity without reducing expenditure. A reduction in spending may create a different choice. The distinction determines what the organization can reasonably commit elsewhere.

Measure the gain before allocating it. Account for the resources needed to produce it, then distinguish freed staff capacity from reduced expenditure. The budget can only use what actually became available.

Once a gain is demonstrated, its destination still requires a decision. The panel's discussion included clinical investment and improved profitability as possible uses of productivity. It did not establish that every improvement automatically flows into R&D. Finance, strategy and R&D leaders therefore need to make the intended use explicit rather than assume that an operational benefit will preserve a development program.

Can the verified gain support the program's next stage? If so, decide where the resource goes. If not, the original tradeoff still needs an answer.

Make the Tradeoff Visible Before Approving the Budget

Return to the development program on the cut list. Ask finance, strategy and R&D leaders to put four things beside the proposed reduction:

  • Immediate savings: what the reduction would save, and when.
  • Capability affected: what the company would become less able to develop or deliver.
  • Milestone preserved or delayed: what would change under the proposed funding level.
  • Evidence for continuing: what supports the investment and what the team must demonstrate next.

Use those four entries to decide what to protect, narrow or stop. Where the consequence remains uncertain, assign the missing evidence to the next review. If productivity gains support the decision, identify the actual resource and its destination.

A budget decision is clearer when everyone can see both the quarter it improves and the capability it changes.

About the Conversation

This article draws on "Pulse on Medtech: The Best Opportunities in Medtech for 2026-2027," a session at The MedTech Conference on October 19, 2026. The discussion examined how medtech companies approach future growth while managing current execution, including investment in internal R&D, acquisitions and emerging companies.

Session contributors, with roles as of October 19, 2026: John Babitt, EY partner and global MedTech leader, moderated the panel. Participants were Mick Farrell (ResMed chairman and CEO), Michael Mahoney (Boston Scientific chairman and CEO), Robbie Marcus (J.P. Morgan medtech analyst) and Ashley McEvoy (Insulet president and CEO).

Resources

The MedTech Conference 2026 agenda

‍

Turn Healthcare Insightinto Accelerated Growth

Our healthcare growth teams work closely with you to design strategies tailored to your unique goals and market dynamics, fully focused on growth.

Book a Strategy Session  →